Updated:
Northview LifeSciences
Northview is a strategic investment and consulting firm focused on the life sciences. Our team combines end-user insight with commercial expertise to develop...
Northview LifeSciences
Northview is a strategic investment and consulting firm focused on the life sciences. Our team combines end-user insight with commercial expertise to develop and advance growth strategies for our clients.
General information
Firm type
Private Equity
Year founded
2012
Location
Region
North America
Country
Canada
City
Vancouver
Corporate office
2820 – 200 Granville St., Vancouver, BC, Canada V6C 1S4
Sector focus
Frequently asked questions
Does Northview LifeSciences operate as a traditional venture capital fund?
No. The firm describes itself as a strategic investment and consulting platform, not a closed-end fund. Its model combines direct investment with commercial-strategy advisory services, and it does not publicly disclose a committed capital pool, fund structure, or limited-partner base.
What therapeutic areas or sectors does Northview target?
Northview's disclosed portfolio ranges from monoclonal antibody platforms, targeted alpha radiation oncology therapies, and ophthalmic specialty drugs to cardiovascular and neurosurgical devices. It also backs digital-health tools, surgical imaging, human-performance supplements, urban agriculture technology, and healthcare staffing — a wider aperture than most dedicated life-science funds.
Who leads investment decisions at Northview LifeSciences?
Northview has not publicly named its principals, investment committee, or deal-team leads. Its materials cite former investment bankers and biotech executives as the core of the group, but no individual biographies or titles are listed on its website as of this profile's publication.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: